Picture1.jpg
ONCOTELIC TO PRESENT AT THE 20TH ANNUAL CONGRESS OF INTERNATIONAL DRUG DISCOVERY SCIENCE & TECHNOLOGY
June 11, 2024 08:10 ET | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its CEO- Dr. Vuong Trieu will speak at the 20th Annual Congress of International Drug...
Picture1.jpg
ONCOTELIC TO PARTICIPATE AT THE BIO INTERNATIONAL 2024 MEETING
May 30, 2024 09:55 ET | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its CEO- Dr. Vuong Trieu will be participating at the BIO International 2024 meeting...
Picture1.jpg
Oncotelic Therapeutics Announces Clinical Linkage of TGFB2 and IFNGR2 in Pediatric DMG Patients
January 16, 2024 08:00 ET | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today the peer reviewed publication of Transforming Growth Factor Beta 2 (TGFB2) and...
Picture1.jpg
Sapu BioScience and Cromos Pharma initiating P201 – A Registrational trial for OT-101 in Pancreatic Cancer
August 23, 2023 07:10 ET | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today its joint venture partner, GMP...
Picture1.jpg
Oncotelic Participating at 2023 BIO International Convention
May 16, 2023 08:00 ET | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), a pioneering developer of therapeutic interventions for rare and orphan diseases...
Picture1.jpg
Oncotelic Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic Cancer
January 25, 2023 08:00 ET | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a clinical stage biotechnology company, with a planned IPO of...
Picture1.jpg
Oncotelic Presents Clinical Data of Confirming TGF-β2 as the appropriate target for gliomas at JCA-AACR Meeting 2022
December 19, 2022 08:00 ET | Oncotelic Therapeutics, Inc.
-Reduced TGF-β2, but not TGF-β1 nor TGF-β3, is associated with improved OS. AGOURA HILLS, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the...
Picture1.jpg
Oncotelic Presenting Data for OT101 Against Pancreatic Cancer (PDAC) at the SITC 37th Annual Meeting
September 28, 2022 08:55 ET | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including...
Picture1.jpg
Oncotelic Presenting Data for OT101 Against Diffuse Intrinsic Pontine Glioma (DIPG) at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
September 14, 2022 08:15 ET | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including...
Picture1.jpg
Oncotelic and Dragon Overseas Capital Limited Completed Joint Venture Transaction
April 04, 2022 07:00 ET | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), today announced the formation of a Joint Venture (“JV”) with Dragon...